These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10388279)

  • 1. [Cardiovascular treatment potentials. P2 receptors important for future drugs].
    Erlinge D
    Lakartidningen; 1999 May; 96(21):2586-9. PubMed ID: 10388279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes.
    von Kügelgen I
    Pharmacol Ther; 2006 Jun; 110(3):415-32. PubMed ID: 16257449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The P2Y12 receptor as a therapeutic target in cardiovascular disease.
    Storey RF
    Platelets; 2001 Jun; 12(4):197-209. PubMed ID: 11454254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiological roles of extracellular nucleotides in glial cells: differential expression of purinergic receptors in resting and activated microglia.
    Bianco F; Fumagalli M; Pravettoni E; D'Ambrosi N; Volonte C; Matteoli M; Abbracchio MP; Verderio C
    Brain Res Brain Res Rev; 2005 Apr; 48(2):144-56. PubMed ID: 15850653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of extracellular purines and pyrimidines on human airway smooth muscle cells.
    Govindaraju V; Martin JG; Maghni K; Ferraro P; Michoud MC
    J Pharmacol Exp Ther; 2005 Nov; 315(2):941-8. PubMed ID: 16099930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
    Siller-Matula J; Schrör K; Wojta J; Huber K
    Thromb Haemost; 2007 Mar; 97(3):385-93. PubMed ID: 17334505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.
    Gachet C
    Pharmacol Ther; 2005 Nov; 108(2):180-92. PubMed ID: 15955565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADP receptors of platelets and their inhibition.
    Gachet C
    Thromb Haemost; 2001 Jul; 86(1):222-32. PubMed ID: 11487010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
    Raju NC; Eikelboom JW; Hirsh J
    Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):766-80. PubMed ID: 18957959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet ADP receptor antagonists: ticlopidine and clopidogrel.
    Jacobson AK
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):55-64. PubMed ID: 15171957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2Y12, a new platelet ADP receptor, target of clopidogrel.
    Herbert JM; Savi P
    Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2Y receptor antagonists in thrombosis.
    Boeynaems JM; van Giezen H; Savi P; Herbert JM
    Curr Opin Investig Drugs; 2005 Mar; 6(3):275-82. PubMed ID: 15816504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modeling of purinergic receptor P2Y12 and interaction with its antagonists.
    Zhan C; Yang J; Dong XC; Wang YL
    J Mol Graph Model; 2007 Jul; 26(1):20-31. PubMed ID: 17110146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P2 receptors and cancer.
    White N; Burnstock G
    Trends Pharmacol Sci; 2006 Apr; 27(4):211-7. PubMed ID: 16530853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet activation by ADP: the role of ADP antagonists.
    Gachet C
    Ann Med; 2000 Dec; 32 Suppl 1():15-20. PubMed ID: 11209975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells.
    Wang L; Jacobsen SE; Bengtsson A; Erlinge D
    BMC Immunol; 2004 Aug; 5():16. PubMed ID: 15291969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uracil nucleotides stimulate human neural precursor cell proliferation and dopaminergic differentiation: involvement of MEK/ERK signalling.
    Milosevic J; Brandt A; Roemuss U; Arnold A; Wegner F; Schwarz SC; Storch A; Zimmermann H; Schwarz J
    J Neurochem; 2006 Nov; 99(3):913-23. PubMed ID: 17076658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
    Storey RF; Wilcox RG; Heptinstall S
    Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
    Packham MA; Mustard JF
    Semin Thromb Hemost; 2005 Apr; 31(2):129-38. PubMed ID: 15852216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.